Abemaciclib + Trastuzumab + Fulvestrant + Standard of Care Single Agent Chemotherapy
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hormone Receptor Positive Breast Cancer
Conditions
Hormone Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer
Trial Timeline
May 23, 2016 → Nov 9, 2023
NCT ID
NCT02675231About Abemaciclib + Trastuzumab + Fulvestrant + Standard of Care Single Agent Chemotherapy
Abemaciclib + Trastuzumab + Fulvestrant + Standard of Care Single Agent Chemotherapy is a phase 2 stage product being developed by Eli Lilly for Hormone Receptor Positive Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02675231. Target conditions include Hormone Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer.
What happened to similar drugs?
9 of 20 similar drugs in Hormone Receptor Positive Breast Cancer were approved
Approved (9) Terminated (2) Active (11)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02675231 | Phase 2 | Completed |
Competing Products
20 competing products in Hormone Receptor Positive Breast Cancer